ID: ALA144047

Max Phase: Preclinical

Molecular Formula: C21H25N5O6S

Molecular Weight: 475.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(OC)c(S(=O)(=O)n2c(N)nc3c2c(=O)n(CC2CC2)c(=O)n3CC2CC2)c1

Standard InChI:  InChI=1S/C21H25N5O6S/c1-31-14-7-8-15(32-2)16(9-14)33(29,30)26-17-18(23-20(26)22)24(10-12-3-4-12)21(28)25(19(17)27)11-13-5-6-13/h7-9,12-13H,3-6,10-11H2,1-2H3,(H2,22,23)

Standard InChI Key:  GOIUEKLXOWTBHN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 475.53

Molecular Weight (Monoisotopic): 475.1526

AlogP: 1.02

#Rotatable Bonds: 8

Polar Surface Area: 140.44

Molecular Species: NEUTRAL

HBA: 11

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa:

CX LogP: 1.26

CX LogD: 1.26

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.51

Np Likeness Score: -1.03

References

1. Buckle DR, Arch JR, Connolly BJ, Fenwick AE, Foster KA, Murray KJ, Readshaw SA, Smallridge M, Smith DG..  (1994)  Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.,  37  (4): [PMID:8120866] [10.1021/jm00030a007]

Source

Source(1):

• Scientific Literature